CN104011076A - 用于制备具有改善性能的抗体的方法 - Google Patents

用于制备具有改善性能的抗体的方法 Download PDF

Info

Publication number
CN104011076A
CN104011076A CN201280065393.3A CN201280065393A CN104011076A CN 104011076 A CN104011076 A CN 104011076A CN 201280065393 A CN201280065393 A CN 201280065393A CN 104011076 A CN104011076 A CN 104011076A
Authority
CN
China
Prior art keywords
glcnac
polypeptide
ser
containing polypeptide
glycans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280065393.3A
Other languages
English (en)
Chinese (zh)
Inventor
T.A.斯塔德海姆
D.库亚
D.札
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN104011076A publication Critical patent/CN104011076A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201280065393.3A 2011-10-31 2012-10-26 用于制备具有改善性能的抗体的方法 Pending CN104011076A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553335P 2011-10-31 2011-10-31
US61/553335 2011-10-31
PCT/US2012/062211 WO2013066761A1 (en) 2011-10-31 2012-10-26 Method for preparing antibodies having improved properties

Publications (1)

Publication Number Publication Date
CN104011076A true CN104011076A (zh) 2014-08-27

Family

ID=48192651

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280065393.3A Pending CN104011076A (zh) 2011-10-31 2012-10-26 用于制备具有改善性能的抗体的方法

Country Status (9)

Country Link
US (1) US20140286946A1 (https=)
EP (1) EP2773661A4 (https=)
JP (1) JP2014532661A (https=)
KR (1) KR20140097245A (https=)
CN (1) CN104011076A (https=)
AU (1) AU2012332840A1 (https=)
CA (1) CA2853809A1 (https=)
IN (1) IN2014CN03072A (https=)
WO (1) WO2013066761A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2739280T3 (es) 2013-07-04 2020-01-30 Glykos Finland Oy Células fúngicas filamentosas deficientes en O-manosiltransferasa y métodos de uso de las mismas
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
KR102512592B1 (ko) 2014-05-27 2023-03-21 아카데미아 시니카 항-ｈｅｒ2 글리코항체 및 이의 용도
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
KR20180086502A (ko) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
KR102659791B1 (ko) * 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896202A (zh) * 2007-12-14 2010-11-24 洛克菲勒大学 具有增强的抗炎活性和降低的细胞毒性的多肽以及相关方法
CN103080130A (zh) * 2010-05-27 2013-05-01 默沙东公司 制备具有改进特性的抗体的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655246A1 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
FR2912154B1 (fr) * 2007-02-02 2012-11-02 Glycode Levures genetiquement modifiees pour la production de glycoproteines homogenes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896202A (zh) * 2007-12-14 2010-11-24 洛克菲勒大学 具有增强的抗炎活性和降低的细胞毒性的多肽以及相关方法
CN103080130A (zh) * 2010-05-27 2013-05-01 默沙东公司 制备具有改进特性的抗体的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUND J.等: "Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.", 《J IMMUNOL.》 *

Also Published As

Publication number Publication date
EP2773661A1 (en) 2014-09-10
WO2013066761A1 (en) 2013-05-10
US20140286946A1 (en) 2014-09-25
AU2012332840A1 (en) 2014-05-15
EP2773661A4 (en) 2015-06-17
KR20140097245A (ko) 2014-08-06
IN2014CN03072A (https=) 2015-07-31
CA2853809A1 (en) 2013-05-10
JP2014532661A (ja) 2014-12-08

Similar Documents

Publication Publication Date Title
US11959118B2 (en) Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc-region
US20140286946A1 (en) Method for preparing antibodies having improved properties
US9328170B2 (en) Method for preparing Fc containing polypeptides having improved properties
US20160215061A1 (en) Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB
US20140302028A1 (en) Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
US20110313137A1 (en) Her2 antibody compositions
WO2015073307A2 (en) Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO HUMAN DC-SIGN
BR112012030179B1 (pt) Polipeptídeo contendo fc

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140827